L-FABP: A novel biomarker of kidney disease

Xu, Yao; Xie, Yuanyuan; Shao, Xinghua; Ni, Zhaohui; Mou, Shan

doi:10.1016/j.cca.2015.03.017

Cited by 113 publications

(111 citation statements)

References 61 publications

(13 reference statements)

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…The estimated sensitivity and specificity of urinary L-FABP were 75% and 78% for the AKI diagnosis, 69% and 43% for prediction of the need for dialysis, and 93% and 79% for in-hospital mortality, respectively [115]. In another systematic review, which included six studies with approximately 1700 patients, the AUC of urinary L-FABP for AKI prediction after cardiac surgery was 0.72 (range, 0.52-0.85) [23,54]. Patients with elevated L-FABP levels measured at the time of ICU admission had a higher risk of AKI development within the first week of admission [30].…”

Section: Kidney Injury Moleculementioning

confidence: 99%

“…In pediatric patients, urinary L-FABP was found to be a sensitive early biomarker of AKI after CPB surgery [54,113]. Higher urinary L-FABP levels are associated with worse outcomes or the need for renal replacement therapy (RRT) in patients with accelerated deterioration of renal function [114].…”

Section: Kidney Injury Moleculementioning

confidence: 99%

“…Within the past 2 decades, a few novel potential biomarkers ( Table 1) that are measurable in urine or plasma of patients with AKI have been identified [49], including neutrophil gelatinase-associated lipocalin (NGAL) [17,50,51], kidney injury molecule 1 (KIM-1) [27,52], interleukin 18 (lL-18) [53], liver-type fatty acid-binding protein (L-FABP) [54], tissue inhibitor of metalloproteinase 2 (TlMP-2), insulin-like growth factorbinding protein 7 (IGFBP7) [33], calprotectin [42], urine angiotensinogen (AGT) [55], and urine microRNAs [47,56].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption

Kashani

Cheungpasitporn

Ronco

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

228

197

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a common complication of critical illnesses and has a significant impact on outcomes, including mortality and morbidities. Unfortunately, apart from prophylactic measures, no effective treatment for this syndrome is known. Therefore, early recognition of AKI not only can provide better opportunities for preventive interventions, but also opens many gates for research and development of effective therapeutic options. Over the last few years, several new AKI biomarkers have been discovered and validated to improve early detection, differential diagnosis, and differentiation of patients into risk groups for progressive renal failure, need for renal replacement therapy (RRT), or death. These novel AKI biomarkers complement serum creatinine (SCr) and urine output, which are the standard diagnostic tools for AKI detection. In this article, we review the available literature on characteristics of promising AKI biomarkers that are currently the focus of preclinical and clinical investigations. These biomarkers include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), liver-type fatty acid-binding protein, interleukin 18 (lL-18), insulin-like growth factor-binding protein 7, tissue inhibitor of metalloproteinase 2 (TIMP-2), calprotectin, urine angiotensinogen (AGT), and urine microRNA. We then describe the clinical performance of these biomarkers for diagnosis and prognostication. We also appraise each AKI biomarker's advantages and limitations as a tool for early AKI recognition and prediction of clinical outcomes after AKI. Finally, we review the current and future states of implementation of biomarkers in the clinical practice.

show abstract

Section: Kidney Injury Moleculementioning

confidence: 99%

Section: Kidney Injury Moleculementioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption

Kashani

Cheungpasitporn

Ronco

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

228

197

View full text Add to dashboard Cite

show abstract

“…Levels of circulating MMPs and TIMPs fluctuate in SLE, and increased MMP-2, MMP-3, MMP-7, TIMP-1 and TIMP-2 probably reflect an aggravated Effective for the early detection and prognosis of several acute kidney diseases [27] Yao Xu [28] ; Michael R. Bennett [13] CXCL9/CXCL10 Urinary CXCL9 promising for clinical decision-making following kidney transplantation Noninvasive biomarkers to screen for subclinical tubulitis [29] Hricik DE [14] ; Rabant M [30] ; Paola Romagnani [31] [TIMP-2 ]* [IGFBP7]…”

Section: T-cell Immunoglobulin Domainmentioning

confidence: 99%

Urine biomarkers in renal allograft

Wang

Lin

Yuan

et al. 2016

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

There is a high risk for the survival of patients with an end-stage renal disease for kidney transplantation. To avoid rejection by strict medication adherence is of utmost importance to avoid the failure of a kidney transplant. It is imperative to develop non-invasive biomarkers to assess immunity risk, and to ultimately provide guidance for therapeutic decision-making following kidney transplantation. Urine biomarkers may represent the promising non-invasive tools that will help in predicting risk or success rates of kidney transplantations. Furthermore, composite urinary biomarkers or urinary biomarker panel array might be critical in improving the sensitivity and specificity in reflecting various risks of kidney failure during transplantation. This review primarily focuses on the role of such biomarkers in predicting chronic kidney disease (CKD) progression and/or cardiovascular disease (CVD) risk in renal allograft.

show abstract

“…L-FABP proksimal tübülüs hücrelerinde tespit edilmiş olup, serbest yağ asitlerine karşı endojen antioksidatif işlev gördüğü yapılan çalışmalarda gösterilmiştir (9,10) .…”

Section: Karaciğer Tipi Yağ Asiti Bağlayıcı Protein (L-fabp)unclassified